PhytoHealth : Public announcement of the company's current R&D progress on anti-osteoporosis.

Close

Today's Information

Provided by: PhytoHealth Corporation
SEQ_NO	4	Date of announcement	2022/02/22	Time of announcement	14:17:01
Subject	Public announcement of the company's current R&D progress on anti-osteoporosis.
Date of events	2022/02/22	To which item it meets	paragraph 51
Statement	1.Date of occurrence of the event:2022/02/22 2.Company name:PhytoHealth Corporation 3.Relationship with the Company (please enter "the company itself" or "subsidiaries"):the company itself 4.Reciprocal shareholding percentage:NA 5.Name of the reporting media:NA 6.Content of the report:NA 7.Cause of occurrence: (1) In accordance with the provisions on financial statements disclosure, the company makes a public announcement on the R&D progress of the one new drugs currently in development. (2) Concerning new drug R&D stages and workflow from bench to market, please consult page 64 of the company's prospectus. As requested by Taiwan Stock Exchange Corporation's letter No.1051801037 issued on Mar.11,2016. (3) New drug in development #1: Anti-osteoporosis Clinical trial for preventing osteoporosis: (a) Trial Title: PH3 for the Prevention of Osteoporosis in Post- menopausal Women in Phase II, Double-Blind, Randomized, and Placebo Controlled Study. (b) Institution: TVGH, CGMH, NTUH and MMH. (c) Trial Update: Phase II clinical study was completed. The company continues to assess the compatibility of clinical trial regulations between Taiwan and China and to explore clinical trial cooperation possbility in accordance with clinical trials harmonization. (d) Filed IND annual report to US-FDA on 2021/05/03. (e) Continuous monitoring of species identification and cultivation. (f) The product development has achieved phased results, and will be jointly developed at an appropriate time and after seeking strategic partners. 8.Countermeasures:NA 9.Any other matters that need to be specified:NA